PL2739293T3 - Sposoby i kompozycje wytwarzania wirusa krowianki - Google Patents

Sposoby i kompozycje wytwarzania wirusa krowianki

Info

Publication number
PL2739293T3
PL2739293T3 PL12746243T PL12746243T PL2739293T3 PL 2739293 T3 PL2739293 T3 PL 2739293T3 PL 12746243 T PL12746243 T PL 12746243T PL 12746243 T PL12746243 T PL 12746243T PL 2739293 T3 PL2739293 T3 PL 2739293T3
Authority
PL
Poland
Prior art keywords
compositions
production
methods
vaccina virus
vaccina
Prior art date
Application number
PL12746243T
Other languages
English (en)
Inventor
David Kirn
John Bell
Original Assignee
Sillajen Biotherapeutics, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sillajen Biotherapeutics, Inc. filed Critical Sillajen Biotherapeutics, Inc.
Publication of PL2739293T3 publication Critical patent/PL2739293T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24132—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24151—Methods of production or purification of viral material

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
PL12746243T 2011-08-05 2012-08-03 Sposoby i kompozycje wytwarzania wirusa krowianki PL2739293T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161515724P 2011-08-05 2011-08-05
EP12746243.0A EP2739293B1 (en) 2011-08-05 2012-08-03 Methods and compositions for production of vaccina virus
PCT/US2012/049550 WO2013022764A1 (en) 2011-08-05 2012-08-03 Methods and compositions for production of vaccina virus

Publications (1)

Publication Number Publication Date
PL2739293T3 true PL2739293T3 (pl) 2020-11-16

Family

ID=46650950

Family Applications (1)

Application Number Title Priority Date Filing Date
PL12746243T PL2739293T3 (pl) 2011-08-05 2012-08-03 Sposoby i kompozycje wytwarzania wirusa krowianki

Country Status (12)

Country Link
US (3) US9719105B2 (pl)
EP (1) EP2739293B1 (pl)
JP (1) JP6243333B2 (pl)
KR (1) KR102022952B1 (pl)
CN (1) CN103732236B (pl)
AU (1) AU2012294606B2 (pl)
BR (1) BR112014000787B1 (pl)
CA (1) CA2841831C (pl)
DK (1) DK2739293T3 (pl)
ES (1) ES2813413T3 (pl)
PL (1) PL2739293T3 (pl)
WO (1) WO2013022764A1 (pl)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3552615B8 (en) 2014-07-16 2022-03-02 Transgene Oncolytic virus for expression of immune checkpoint modulators
ES3011733T3 (en) 2015-02-13 2025-04-08 Transgene Immunotherapeutic vaccine and antibody combination therapy
WO2016131945A1 (en) 2015-02-20 2016-08-25 Transgene Sa Combination product with autophagy modulator
CN108025056B (zh) 2015-06-19 2022-01-14 新罗杰股份有限公司 用于病毒栓塞的组合物和方法
CN106676071B (zh) * 2015-11-06 2019-07-19 天士力创世杰（天津）生物制药有限公司 HeLa-F细胞及其用途
EP3452081A1 (en) 2016-05-04 2019-03-13 Transgene SA Combination therapy with cpg tlr9 ligand
EP3522920A2 (en) 2016-10-10 2019-08-14 Transgene SA Immunotherapeutic product and mdsc modulator combination therapy
WO2018091680A1 (en) 2016-11-18 2018-05-24 Transgene Sa Cowpox-based oncolytic vectors
EP3562946B1 (en) 2016-12-28 2021-11-24 Transgene SA Oncolytic viruses and therapeutic molecules
AU2018254626B2 (en) 2017-04-21 2023-12-21 Sillajen, Inc. Oncolytic vaccinia virus and checkpoint inhibitor combination therapy
JP7334124B2 (ja) 2017-06-21 2023-08-28 トランジェーヌ 個別化ワクチン
WO2019020543A1 (en) 2017-07-28 2019-01-31 Transgene Sa ONCOLYTIC VIRUSES EXPRESSING AGENTS TARGETING METABOLIC IMMUNE MODULATORS
JP7551496B2 (ja) 2017-10-31 2024-09-17 カリヴィル イムノセラピューティクス， インコーポレイテッド 全身送達のためのプラットフォーム腫瘍溶解性ベクター
WO2020011754A1 (en) 2018-07-09 2020-01-16 Transgene Chimeric vaccinia viruses
EP3617230A1 (en) 2018-09-03 2020-03-04 BioInvent International AB Novel antibodies and nucleotide sequences, and uses thereof
CN113330111A (zh) * 2018-11-21 2021-08-31 西方溶瘤细胞有限公司 病毒的制造
CN113453712A (zh) 2018-12-28 2021-09-28 特兰斯吉恩股份有限公司 M2缺陷型痘病毒
KR102228267B1 (ko) 2019-01-25 2021-03-17 바이로큐어 주식회사 Bhk-21 세포를 이용한 바이러스 생산방법
CN112143693B (zh) * 2019-06-28 2024-12-27 杭州康万达医药科技有限公司 一种生产病毒的方法及收获液组合物
EP3842065A1 (en) 2019-12-23 2021-06-30 Transgene Process for designing a recombinant poxvirus for a therapeutic vaccine
BR112022026319A2 (pt) * 2020-06-22 2023-01-17 Kolon Life Science Inc Método para produção em massa de vírus vaccinia por meio do uso de células em suspensão
CN116322740A (zh) 2020-07-13 2023-06-23 特兰斯吉恩股份有限公司 免疫抑制的治疗
PE20231175A1 (es) 2020-11-19 2023-08-01 Kalivir Immunotherapeutics Inc Inmunoterapia oncolitica por remodelacion del microambiente tumoral
WO2022148736A1 (en) 2021-01-05 2022-07-14 Transgene Vectorization of muc1 t cell engager
IL316712B2 (en) 2021-04-30 2025-12-01 Kalivir Immunotherapeutics Inc Oncolytic viruses for modified mhc expression
WO2023025899A2 (en) 2021-08-26 2023-03-02 Transgene Delivery system for targeting genes of the interferon pathway
TW202321458A (zh) 2021-09-22 2023-06-01 瑞典商生物創新國際公司 新穎抗體組合及其用途
GB2614309A (en) 2021-12-24 2023-07-05 Stratosvir Ltd Improved vaccinia virus vectors
CN114395538A (zh) * 2022-01-19 2022-04-26 和元生物技术（上海）股份有限公司 一种促进重组病毒载体向细胞外分泌的方法
WO2023213763A1 (en) 2022-05-02 2023-11-09 Transgene Poxvirus encoding a binding agent comprising an anti- pd-l1 sdab
WO2023213764A1 (en) 2022-05-02 2023-11-09 Transgene Fusion polypeptide comprising an anti-pd-l1 sdab and a member of the tnfsf
AU2023300419A1 (en) 2022-07-01 2025-01-02 Transgene Fusion protein comprising a surfactant-protein-d and a member of the tnfsf
WO2024038175A1 (en) 2022-08-18 2024-02-22 Transgene Chimeric poxviruses
EP4677076A1 (en) * 2023-03-10 2026-01-14 Bavarian Nordic A/S Methods of isolating poxviruses from avian cell cultures
WO2026041811A1 (en) 2024-08-23 2026-02-26 Transgene Recombinant poxvirus and method for regulating the expression of toxic conditional gene products of said recombinant poxvirus in a producing cell

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6267965B1 (en) * 1981-12-24 2001-07-31 Virogenetics Corporation Recombinant poxvirus—cytomegalovirus compositions and uses
UA68327C2 (en) * 1995-07-04 2004-08-16 Gsf Forschungszentrum Fur Unwe A recombinant mva virus, an isolated eukaryotic cell, infected with recombinant mva virus, a method for production in vitro of polypeptides with use of said cell, a method for production in vitro of virus parts (variants), vaccine containing the recombinant mva virus, a method for immunization of animals
US7445924B2 (en) * 2000-11-23 2008-11-04 Bavarian Nordic A/S Modified Vaccinia Ankara virus variant and cultivation method
CN101676389A (zh) * 2000-11-23 2010-03-24 巴法里安诺迪克有限公司 改良安卡拉痘苗病毒变体
EP2269619A1 (en) 2002-08-12 2011-01-05 Jennerex Biotherapeutics ULC Methods and compositions concerning poxviruses and cancer
US8574595B2 (en) * 2005-04-11 2013-11-05 Crucell Holland B.V. Virus purification using ultrafiltration
CN101351213B (zh) * 2005-09-07 2013-10-02 詹纳里克斯公司 使用表达gm-csf的痘病毒系统性治疗转移性癌和/或全身散布性癌
CN101557824B (zh) * 2006-08-07 2012-01-25 财团法人化学及血清疗法研究所 活牛痘疫苗的制备方法
KR20080084528A (ko) 2007-03-15 2008-09-19 제네렉스 바이오테라퓨틱스 인크. 종양살상형 백시니아 바이러스 암 치료
US8003364B2 (en) * 2007-05-14 2011-08-23 Bavarian Nordic A/S Purification of vaccinia viruses using hydrophobic interaction chromatography
WO2009048769A2 (en) * 2007-10-10 2009-04-16 Kirin Pharma Kabushiki Kaisha Vaccinia virus h3l and b5r specific monoclonal antibodies and methods of making and using same
EP2085092A1 (en) 2008-01-29 2009-08-05 Bayer Schering Pharma Aktiengesellschaft Attenuated oncolytic paramyxoviruses encoding avian cytokines
JP2013500717A (ja) 2009-07-28 2013-01-10 コーニング インコーポレイテッド 細胞を培養するための合成マイクロキャリア
ES2671570T3 (es) * 2009-09-14 2018-06-07 Sillajen Biotherapeutics, Inc. Terapia combinada contra el cáncer con virus oncolítico de vaccinia

Also Published As

Publication number Publication date
CA2841831C (en) 2019-12-31
EP2739293A1 (en) 2014-06-11
KR20140058601A (ko) 2014-05-14
US10767166B2 (en) 2020-09-08
CN103732236A (zh) 2014-04-16
BR112014000787A2 (pt) 2017-07-11
WO2013022764A1 (en) 2013-02-14
JP2014521353A (ja) 2014-08-28
KR102022952B1 (ko) 2019-09-20
EP2739293B1 (en) 2020-06-10
US9719105B2 (en) 2017-08-01
BR112014000787B1 (pt) 2021-04-13
US20140162342A1 (en) 2014-06-12
CA2841831A1 (en) 2013-02-14
JP6243333B2 (ja) 2017-12-06
AU2012294606A1 (en) 2014-01-23
US10202581B2 (en) 2019-02-12
DK2739293T3 (da) 2020-08-24
ES2813413T3 (es) 2021-03-23
US20190169578A1 (en) 2019-06-06
CN103732236B (zh) 2017-09-15
US20170298324A1 (en) 2017-10-19
AU2012294606B2 (en) 2016-10-06

Similar Documents

Publication Publication Date Title
ZA201305150B (en) Processes for preparing isoquinolinones and solid forms of isoquinolinones
IL229830B (en) Novel compinds as modulatord of gpr-119
IL229419A0 (en) Heat-stable vaccines and methods for their preparation
PH12013501969A1 (en) Compositions and methods for inhibiting expression of tmprss6 gene
ZA201307914B (en) Compositions and methods for inhibiting gene expression of hepatitis b virus
EP2712362A4 (en) MANUFACTURE OF LACTO-N-TETRAOSE
EP2771030A4 (en) COMPOSITIONS AND METHOD FOR THE TREATMENT OF PROTEINOPATHIES
ZA201306316B (en) Methods and compositions for preparing noribogaine from voacangine
GB2503842B (en) Composition and method of manufacture
EP2670790A4 (en) METHOD FOR FLAME-RESISTANT POLYETHYLENE PROCESSED AT HIGH TEMPERATURES
PL2785701T3 (pl) Krystaliczna postać kabazytakselu i sposób jej otrzymywania
PL2668163T3 (pl) Sposób wytwarzania 6-podstawionych 4-amino-3-chloro-5-fluoro-pikolinianów
EP2747975A4 (en) MANUFACTURED ARTICLE AND PROCESS FOR PREPARING THE SAME
GB201120696D0 (en) Production of mono-cystalline silicon
SG2014010441A (en) Preparation process of l-methionine
GB201220155D0 (en) Method of manufacture
GB201109416D0 (en) Methods of mass spectrometry
IL237862A0 (en) Methods to reduce the formation of scale
EP2684869A4 (en) PREPARATION OF 3-MERCAPOTOPROPIONATES
EP2780475A4 (en) PROCESS FOR ALL-PECIFIC AMPLIFICATION
IL239623A0 (en) Methods and preparations for administering oxybutynin
IL226329A (en) Method for preparing methaxalone
SG11201402899TA (en) Methods and compositions for treating viral diseases
GB201114798D0 (en) Method of modifying surfaces
GB201119607D0 (en) Method of manufacture